AACR: new second-line survival data for Opdivo

Bristol-Myers Squibb (NYSE: BMY) has presented new survival data for Opdivo (nivolumab) at the annual meeting of the American Association for Cancer Research (AACR).

The new pooled analyses consider survival data from four studies, CheckMate -017, -057, -063 and -003, looking at people with advanced non-small cell lung cancer (NSCLC), in the second-line setting.

In the pooled analysis of all four studies, 14% of all Opdivo-treated patients were alive at four years. An analysis of the two Phase III trials, CheckMate -017 and -057, showed the four-year OS rate for the Opdivo group was 14%, compared to 5%.